{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:46:49Z","timestamp":1783003609839,"version":"3.54.5"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Brain"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Huntington Disease (HD) is a neurodegenerative disorder resulting from the expansion of polyglutamine stretch in the huntingtin protein (Htt). Mutant HTT (mHtt) leads to progressive impairment of several molecular pathways that have been linked to disease pathogenesis. Defects in the production of a number of neurotrophic factors have been described as important determinants contributing to the development of HD. We have previously demonstrated that production of transforming growth factor-\u03b21 (TGF-\u03b21) is also deregulated in HD. Peripheral levels of TGF-\u03b21 were markedly reduced early in the disease and returned to normal levels with disease severity. However, the cause and the biochemical origin of such abnormalities are still unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We report here that the abnormal production of peripheral TGF-\u03b21 depends on the changes in the percentage of TGF-\u03b21-producing macrophages along disease course. Variation in the number of TGF-\u03b21-producing macrophages resulted from differential activation state of the same cells, which displayed phenotypic and functional heterogeneity throughout the clinical course of HD. We further demonstrated that, similar to the periphery, the number of TGF-\u03b21-immunoreactive cells in human post-mortem brain with HD, varied with neuropathological changes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our data indicate that reduced bioavailability of TGF-\u03b21 in the serum of HD subjects is attributable to the variation of the number of TGF-\u03b21-producing macrophages. Macrophages display a differential ability to produce TGF-\u03b21, which reflects diversity in cells polarization throughout the disease course. Besides elucidating the biochemical origin of TGF-\u03b21 fluctuations in HD, our study highlights an interesting parallelism between periphery and central compartment and underlines the potential of TGF-\u03b21 as a possible indicator suitable for prediction of disease onset in HD.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1756-6606-6-55","type":"journal-article","created":{"date-parts":[[2013,12,13]],"date-time":"2013-12-13T12:05:43Z","timestamp":1386936343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Changes of peripheral TGF-\u03b21 depend on monocytes-derived macrophages in Huntington disease"],"prefix":"10.1186","volume":"6","author":[{"given":"Alba","family":"Di Pardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Alberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Maglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etty P","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Elifani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Battaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla L","family":"Busceti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Nicoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JeanPaul G","family":"Vonsattel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Squitieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,13]]},"reference":[{"key":"332_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1474-4422(09)70178-4","volume":"8","author":"JM van der Burg","year":"2009","unstructured":"van der Burg JM, Bj\u00f6rkqvist M, Brundin P: Beyond the brain: widespread pathology in Huntington\u2019s disease. Lancet Neurol. 2009, 8: 765-774. 10.1016\/S1474-4422(09)70178-4.","journal-title":"Lancet Neurol"},{"key":"332_CR2","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1084\/jem.20080178","volume":"8","author":"M Bj\u00f6rkqvist","year":"2008","unstructured":"Bj\u00f6rkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Pouladi MA, Hayden MR, Khalili-Shirazi A, Lowdell MW, Brundin P, Bates GP, Leavitt BR, M\u00f6ller T, Tabrizi SJ: A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease. J Exp Med. 2008, 8: 1869-1877.","journal-title":"J Exp Med"},{"key":"332_CR3","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1172\/JCI64565","volume":"10","author":"A Weiss","year":"2012","unstructured":"Weiss A, Tr\u00e4ger U, Wild EJ, Grueninger S, Farmer R, Landles C, Scahill RI, Lahiri N, Haider S, Macdonald D, Frost C, Bates GP, Bilbe G, Kuhn R, Andre R, Tabrizi SJ: Mutant huntingtin fragmentation in immune cells tracks Huntington\u2019s disease progression. J Clin Invest. 2012, 10: 3731-3736.","journal-title":"J Clin Invest"},{"key":"332_CR4","doi-asserted-by":"publisher","first-page":"4737","DOI":"10.1172\/JCI64484","volume":"12","author":"W Kwan","year":"2012","unstructured":"Kwan W, Tr\u00e4ger U, Davalos D, Chou A, Bouchard J, Andre R, Miller A, Weiss A, Giorgini F, Cheah C, M\u00f6ller T, Stella N, Akassoglou K, Tabrizi SJ, Muchowski PJ: Mutant huntingtin impairs immune cell migration in Huntington disease. J Clin Invest. 2012, 12: 4737-4747.","journal-title":"J Clin Invest"},{"key":"332_CR5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1126\/science.1059581","volume":"5529","author":"C Zuccato","year":"2001","unstructured":"Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, Timmusk T, Sipione S, Cattaneo E, et al: Loss of huntingtin-mediated BDNF gene transcription in Huntington\u2019s disease. Science. 2001, 5529: 493-498.","journal-title":"Science"},{"key":"332_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1006\/exnr.2001.7859","volume":"2","author":"S Marco","year":"2002","unstructured":"Marco S, Canudas AM, Canals JM, Gavald\u00e0 N, P\u00e9rez-Navarro E, Alberch J: Excitatory amino acids differentially regulate the expression of GDNF, neurturin, and their receptors in the adult rat striatum. Exp Neurol. 2002, 2: 243-252.","journal-title":"Exp Neurol"},{"key":"332_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1196\/annals.1418.005","volume":"1144","author":"MP Mattson","year":"2008","unstructured":"Mattson MP: Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann N Y Acad Sci. 2008, 1144: 97-112. 10.1196\/annals.1418.005.","journal-title":"Ann N Y Acad Sci"},{"key":"332_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cell.2004.06.018","volume":"1","author":"LR Gauthier","year":"2004","unstructured":"Gauthier LR, Charrin BC, Borrell-Pag\u00e8s M, Dompierre JP, Rangone H, Cordeli\u00e8res FP, De Mey J, MacDonald ME, Lessmann V, Humbert S, Saudou F: Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesiculartransport along microtubules. Cell. 2004, 1: 127-138.","journal-title":"Cell"},{"key":"332_CR9","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.nbd.2006.01.004","volume":"3","author":"D Boche","year":"2006","unstructured":"Boche D, Cunningham C, Docagne F, Scott H, Perry VH: TGFbeta1 regulates the inflammatory response during chronic neurodegeneration. Neurobiol Dis. 2006, 3: 638-650.","journal-title":"Neurobiol Dis"},{"key":"332_CR10","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/j.1582-4934.2010.01011.x","volume":"3","author":"G Battaglia","year":"2011","unstructured":"Battaglia G, Cannella M, Riozzi B, Orobello S, Maat-Schieman ML, Aronica E, Busceti CL, Ciarmiello A, Alberti S, Amico E, Sassone J, Sipione S, Bruno V, Frati L, Nicoletti F, Squitieri F: Early defect of transforming growth factor \u03b21 formation in Huntington\u2019s disease. J Cell Mol Med. 2011, 3: 555-571.","journal-title":"J Cell Mol Med"},{"key":"332_CR11","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1189\/jlb.71.5.731","volume":"5","author":"S Dennler","year":"2002","unstructured":"Dennler S, Goumans MJ, ten Dijke P: Transforming growth factor beta signal transduction. J Leuk Biol. 2002, 5: 731-740.","journal-title":"J Leuk Biol"},{"key":"332_CR12","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0896-6273(03)00766-9","volume":"6","author":"TC Brionne","year":"2003","unstructured":"Brionne TC, Tesseur I, Masliah E, Wyss-Coray T: Loss of TGF-beta 1 leads to increased neuronal cell death and microgliosis in mouse brain. Neuron. 2003, 6: 1133-1145.","journal-title":"Neuron"},{"key":"332_CR13","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2174\/156720506779025297","volume":"5","author":"I Tesseur","year":"2006","unstructured":"Tesseur I, Wyss-Coray T: A role for TGF-beta signaling in neurodegeneration: evidence from genetically engineered models. Curr Alzheimer Res. 2006, 5: 505-513.","journal-title":"Curr Alzheimer Res"},{"key":"332_CR14","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1002\/jnr.21072","volume":"8","author":"HG Lee","year":"2006","unstructured":"Lee HG, Ueda M, Zhu X, Perry G, Smith MA: Ectopic expression of phospho-Smad2 in Alzheimer\u2019s disease: uncoupling of the transforming growth factor-beta pathway?. J Neurosci Res. 2006, 8: 1856-1861.","journal-title":"J Neurosci Res"},{"key":"332_CR15","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1172\/JCI27341","volume":"11","author":"I Tesseur","year":"2006","unstructured":"Tesseur I, Zou K, Esposito L, Bard F, Berber E, Can JV, Lin AH, Crews L, Tremblay P, Mathews P, Mucke L, Masliah E, Wyss-Coray T: Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer\u2019s pathology. J Clin Invest. 2006, 11: 3060-3069.","journal-title":"J Clin Invest"},{"key":"332_CR16","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1111\/j.1460-9568.2006.05109.x","volume":"8","author":"U Ueberham","year":"2006","unstructured":"Ueberham U, Ueberham E, Gruschka H, Arendt T: Altered subcellular location of phosphorylated Smads in Alzheimer\u2019s disease. Eur J Neurosci. 2006, 8: 2327-2334.","journal-title":"Eur J Neurosci"},{"key":"332_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/nen.0b013e3180303b93","volume":"2","author":"KA Chalmers","year":"2007","unstructured":"Chalmers KA, Love S: Neurofibrillary tangles may interfere with Smad 2\/3 signaling in neurons. J Neuropathol Exp Neurol. 2007, 2: 158-167.","journal-title":"J Neuropathol Exp Neurol"},{"key":"332_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1006\/cyto.2002.2005","volume":"5","author":"J Itzecka","year":"2002","unstructured":"Itzecka J, Stelmasiak Z, Dobosz B: Transforming growth factor-Beta 1 (Tgf-Beta in patients with amyotrophic lateral sclerosis. Cytokine. 2002, 5: 239-243.","journal-title":"Cytokine"},{"key":"332_CR19","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1083\/jcb.117.2.395","volume":"2","author":"D Lindholm","year":"1992","unstructured":"Lindholm D, Castren E, Kiefer R, Zafra F, Thoenen H: Transforming growth factor-beta 1 in the rat brain: increase after injury and inhibition of astrocyte proliferation. J Cell Biol. 1992, 2: 395-400.","journal-title":"J Cell Biol"},{"key":"332_CR20","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1161\/01.STR.27.5.852","volume":"5","author":"J Krupinski","year":"1996","unstructured":"Krupinski J, Kumar P, Kumar S, Kaluza J: Increased expression of TGF-beta 1 in brain tissue after ischemic stroke in humans. Stroke. 1996, 5: 852-857.","journal-title":"Stroke"},{"key":"332_CR21","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1097\/01.WCB.0000090080.64176.44","volume":"10","author":"D Boche","year":"2003","unstructured":"Boche D, Cunningham C, Gauldie J, Perry VH: Transforming growth factor-beta 1-mediated neuroprotection against excitotoxic injury in vivo. J Cereb Blood Flow Metab. 2003, 10: 1174-1182.","journal-title":"J Cereb Blood Flow Metab"},{"key":"332_CR22","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1038\/labinvest.3700669","volume":"11","author":"GJ Prud\u2019homme","year":"2007","unstructured":"Prud\u2019homme GJ: Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest. 2007, 11: 1077-1091.","journal-title":"Lab Invest"},{"key":"332_CR23","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nri2448","volume":"12","author":"DM Mosser","year":"2008","unstructured":"Mosser DM, Edwards JP: Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008, 12: 958-969.","journal-title":"Nat Rev Immunol"},{"key":"332_CR24","doi-asserted-by":"publisher","first-page":"342","DOI":"10.4049\/jimmunol.175.1.342","volume":"1","author":"RD Stout","year":"2005","unstructured":"Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, Suttles J: Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol. 2005, 1: 342-349.","journal-title":"J Immunol"},{"key":"332_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nri978","volume":"1","author":"S Gordon","year":"2003","unstructured":"Gordon S: Alternative activation of macrophages. Nat Rev Immunol. 2003, 1: 23-35.","journal-title":"Nat Rev Immunol"},{"key":"332_CR26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.neuron.2009.08.039","volume":"1","author":"KM Lucin","year":"2009","unstructured":"Lucin KM, Wyss-Coray T: Immune activation in brain aging and neurodegeneration: too much or too little?. Neuron. 2009, 1: 110-122.","journal-title":"Neuron"},{"key":"332_CR27","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.it.2004.09.015","volume":"12","author":"A Mantovani","year":"2004","unstructured":"Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 12: 677-686.","journal-title":"Trends Immunol"},{"key":"332_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0165-0173(98)00004-6","volume":"1","author":"B Connor","year":"1998","unstructured":"Connor B, Dragunow M: The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res Brain Res Rev. 1998, 1: 1-39.","journal-title":"Brain Res Brain Res Rev"},{"key":"332_CR29","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/jnen\/62.4.340","volume":"4","author":"A Kruttgen","year":"2003","unstructured":"Kruttgen A, Saxena S, Evangelopoulos ME, Weis J: Neurotrophins and neurodegenerative diseases: receptors stuck in traffic?. J Neuropathol Exp Neurol. 2003, 4: 340-350.","journal-title":"J Neuropathol Exp Neurol"},{"key":"332_CR30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0301-0082(00)00014-9","volume":"1","author":"MG Murer","year":"2001","unstructured":"Murer MG, Yan Q, Raisman-Vozari R: Brain-derived neurotrophic factor in the control human brain, and in Alzheimer\u2019s disease and Parkinson\u2019s disease. Prog Neurobiol. 2001, 1: 71-124.","journal-title":"Prog Neurobiol"},{"key":"332_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.phrs.2005.01.001","volume":"2","author":"C Zuccato","year":"2005","unstructured":"Zuccato C, Liber D, Ramos C, Tarditi A, Rigamonti D, Tartari M, Valenza M, Cattaneo E: Progressive loss of BDNF in a mouse model of Huntington\u2019s disease and rescue by BDNF delivery. Pharmacol Res. 2005, 2: 133-139.","journal-title":"Pharmacol Res"},{"key":"332_CR32","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1100\/2011\/213962","volume":"11","author":"L Cassetta","year":"2011","unstructured":"Cassetta L, Cassol E, Poli G: Macrophage polarization in health and disease. ScientificWorldJournal. 2011, 11: 2391-2402.","journal-title":"ScientificWorldJournal"},{"key":"332_CR33","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.immuni.2005.10.001","volume":"4","author":"A Mantovani","year":"2005","unstructured":"Mantovani A, Sica A, Locati M: Macrophage polarization comes of age. Immunity. 2005, 4: 344-346.","journal-title":"Immunity"},{"key":"332_CR34","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1172\/JCI59643","volume":"3","author":"A Sica","year":"2012","unstructured":"Sica A, Mantovani A: Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012, 3: 787-795.","journal-title":"J Clin Invest"},{"key":"332_CR35","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ni.1937","volume":"10","author":"SK Biswas","year":"2010","unstructured":"Biswas SK, Mantovani A: Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010, 10: 889-896.","journal-title":"Nat Immunol"},{"key":"332_CR36","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/nri1733","volume":"12","author":"S Gordon","year":"2005","unstructured":"Gordon S, Taylor PR: Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005, 12: 953-964.","journal-title":"Nat Rev Immunol"},{"key":"332_CR37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1172\/JCI11916","volume":"3","author":"MP Mattson","year":"2001","unstructured":"Mattson MP, Camandola S: NF-kappaB in neuronal plasticity and neurodegenerative disorders. J Clin Invest. 2001, 3: 247-254.","journal-title":"J Clin Invest"},{"key":"332_CR38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1365-2249.2004.02342.x","volume":"1","author":"F Driessler","year":"2004","unstructured":"Driessler F, Venstrom K, Sabat R, Asadullah K, Schottelius AJ: Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50. Clin Exp Immunol. 2004, 1: 64-73.","journal-title":"Clin Exp Immunol"},{"key":"332_CR39","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1093\/carcin\/bgh198","volume":"10","author":"J Hu","year":"2004","unstructured":"Hu J, Nakano H, Sakurai H, Colburn NH: Insufficient p65 phosphorylation at S536 specifically contributes to the lack of NF-kappaB activation and transformation in resistant JB6 cells. Carcinogenesis. 2004, 10: 1991-2003.","journal-title":"Carcinogenesis"},{"key":"332_CR40","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1172\/JCI31422","volume":"5","author":"A Sica","year":"2007","unstructured":"Sica A, Bronte V: Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007, 5: 1155-1166.","journal-title":"J Clin Invest"},{"key":"332_CR41","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1161\/01.CIR.100.12.1330","volume":"12","author":"SF Liu","year":"1999","unstructured":"Liu SF, Ye X, Malik AB: Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents In vivo expression of proinflammatory genes. Circulation. 1999, 12: 1330-1337.","journal-title":"Circulation"},{"key":"332_CR42","doi-asserted-by":"publisher","first-page":"762","DOI":"10.4049\/jimmunol.164.2.762","volume":"2","author":"A Sica","year":"2000","unstructured":"Sica A, Saccani A, Bottazzi B, Polentarutti N, Vecchi A, van Damme J, Mantovani A: Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol. 2000, 2: 762-767.","journal-title":"J Immunol"},{"key":"332_CR43","doi-asserted-by":"publisher","first-page":"14978","DOI":"10.1073\/pnas.0809784106","volume":"35","author":"C Porta","year":"2009","unstructured":"Porta C, Rimoldi M, Raes G, Brys L, Ghezzi P, Di Liberto D, Dieli F, Ghisletti S, Natoli G, De Baetselier P, Mantovani A, Sica A: Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci U S A. 2009, 35: 14978-14983.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"332_CR44","doi-asserted-by":"publisher","first-page":"L622","DOI":"10.1152\/ajplung.00477.2005","volume":"4","author":"SF Liu","year":"2006","unstructured":"Liu SF, Malik AB: NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol. 2006, 4: L622-L645.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"332_CR45","doi-asserted-by":"publisher","first-page":"7999","DOI":"10.1523\/JNEUROSCI.2675-04.2004","volume":"37","author":"A Khoshnan","year":"2004","unstructured":"Khoshnan A, Ko J, Watkin EE, Paige LA, Reinhart PH, Patterson PH: Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J Neurosci. 2004, 37: 7999-8008.","journal-title":"J Neurosci"},{"key":"332_CR46","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/hmg\/ddt036","volume":"9","author":"HY Hsiao","year":"2013","unstructured":"Hsiao HY, Chen YC, Chen HM, Tu PH, Chern Y: A critical role of astrocyte-mediated nuclear factor-\u03baB-dependent inflammation in Huntington\u2019s disease. Hum Mol Genet. 2013, 9: 1826-1842.","journal-title":"Hum Mol Genet"},{"key":"332_CR47","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s00018-010-0305-y","volume":"11","author":"S Reijonen","year":"2010","unstructured":"Reijonen S, Kukkonen JP, Hyrskyluoto A, Kivinen J, Kairisalo M, Takei N, Lindholm D, Korhonen L: Downregulation of NF-kappaB signaling by mutant huntingtin proteins induces oxidative stress and cell death. Cell Mol Life Sci. 2010, 11: 1929-1941.","journal-title":"Cell Mol Life Sci"},{"key":"332_CR48","doi-asserted-by":"publisher","first-page":"26041","DOI":"10.1074\/jbc.M602222200","volume":"36","author":"S Cao","year":"2006","unstructured":"Cao S, Zhang X, Edwards JP, Mosser DM: NF-kappaB1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages. J Biol Chem. 2006, 36: 26041-26050.","journal-title":"J Biol Chem"},{"key":"332_CR49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1189\/jlb.0904484","volume":"1","author":"G Gr\u00fctz","year":"2005","unstructured":"Gr\u00fctz G: New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. J Leukoc Biol. 2005, 1: 3-15.","journal-title":"J Leukoc Biol"},{"key":"332_CR50","doi-asserted-by":"crossref","first-page":"9594","DOI":"10.1523\/JNEUROSCI.18-23-09594.1998","volume":"23","author":"V Bruno","year":"1998","unstructured":"Bruno V, Battaglia G, Casabona G, Copani A, Caciagli F, Nicoletti F: Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J Neurosci. 1998, 23: 9594-9600.","journal-title":"J Neurosci"},{"key":"332_CR51","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10072-008-0969-3","volume":"4","author":"F Squitieri","year":"2008","unstructured":"Squitieri F, Cannella M, Frati L: Molecular medicine: predicting and preventing Huntington\u2019s disease. Neurol Sci. 2008, 4: 205-207.","journal-title":"Neurol Sci"},{"key":"332_CR52","first-page":"264","volume":"3\u20134","author":"Declaration of Helsinki","year":"1991","unstructured":"Declaration of Helsinki: Law, medicine & health care: a publication of the American. Soc Law Med. 1991, 3\u20134: 264-265.","journal-title":"Soc Law Med"},{"key":"332_CR53","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"Huntington Study Group","year":"1996","unstructured":"Huntington Study Group: The Unified Huntington\u2019s Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord. 1996, 11: 136-142.","journal-title":"Mov Disord"},{"key":"332_CR54","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"3","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR: \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psych Res. 1975, 3: 189-198.","journal-title":"J Psych Res"},{"key":"332_CR55","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1093\/brain\/awg077","volume":"4","author":"F Squitieri","year":"2003","unstructured":"Squitieri F, Gellera C, Cannella M, Mariotti C, Cislaghi G, Rubinsztein DC, Almqvist EW, Turner D, Bachoud-L\u00e9vi AC, Simpson SA, Delatycki M, Maglione V, Hayden MR, Donato SD: Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain. 2003, 4: 946-955.","journal-title":"Brain"},{"key":"332_CR56","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1212\/WNL.57.4.658","volume":"4","author":"JS Paulsen","year":"2001","unstructured":"Paulsen JS, Zhao H, Stout JC, Brinkman RR, Guttman M, Ross CA, Como P, Manning C, Hayden MR, Shoulson I: Huntington Study Group. Clinical markers of early disease in persons near onset of Huntington\u2019s disease. Neurology. 2001, 4: 658-662.","journal-title":"Neurology"},{"key":"332_CR57","first-page":"1202","volume":"5","author":"RR Brinkman","year":"1997","unstructured":"Brinkman RR, Mezei MM, Theilmann J, Almqvist E, Hayden MR: The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet. 1997, 5: 1202-1210.","journal-title":"Am J Hum Genet"},{"key":"332_CR58","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","volume":"4","author":"DR Langbehn","year":"2004","unstructured":"Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR: A new model for prediction of the age of onset and penetrance for Huntington\u2019s disease based on CAG length. Clinic Genet. 2004, 4: 267-277.","journal-title":"Clinic Genet"},{"key":"332_CR59","first-page":"499","volume":"8","author":"M Di Paola","year":"2012","unstructured":"Di Paola M, Luders E, Rubino IA, Siracusano A, Manfredi G, Girardi P, Martinotti G, Thompson PM, Chou YY, Toga AW, Martinotti G, Caltagirone C, Spalletta G: The structure of the corpus callosum in obsessive compulsive disorder. Eur Psychiatry. 2012, 8: 499-506.","journal-title":"Eur Psychiatry"},{"key":"332_CR60","first-page":"1625","volume":"7","author":"C S\u00e1nchez-Casta\u00f1eda","year":"2012","unstructured":"S\u00e1nchez-Casta\u00f1eda C, Cherubini A, Elifani F, P\u00e9ran P, Orobello S, Capelli G, Sabatini U, Squitieri F: Seeking huntington disease biomarkers by multimodal, cross-sectional basal ganglia imaging. Hum Brain Mapp. 2012, 7: 1625-1635.","journal-title":"Hum Brain Mapp"},{"key":"332_CR61","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/ana.410410521","volume":"5","author":"JB Penney","year":"1997","unstructured":"Penney JB, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH: CAG repeat number governs the development rate of pathology in Huntington\u2019s disease. Ann Neurol. 1997, 5: 689-692.","journal-title":"Ann Neurol"},{"key":"332_CR62","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/00005072-199111000-00005","volume":"6","author":"RH Myers","year":"1991","unstructured":"Myers RH, Vonsattel JP, Paskevich PA, Kiely DK, Stevens TJ, Cupples LA, Richardson EP, Bird ED: Decreased neuronal and increased oligodendroglial densities in Huntington\u2019s disease caudate nucleus. J Neuropathol Exp Neurol. 1991, 6: 729-742.","journal-title":"J Neuropathol Exp Neurol"},{"key":"332_CR63","first-page":"452","volume":"2","author":"K Marder","year":"2000","unstructured":"Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, Orme C, Paulsen J, Penney JB, Siemers E, Shoulson I: Rate of functional decline in Huntington\u2019s disease. Huntington Study Group Neurol. 2000, 2: 452-458.","journal-title":"Huntington Study Group Neurol"},{"key":"332_CR64","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/sj.bjp.0701124","volume":"2","author":"F Gantner","year":"1997","unstructured":"Gantner F, Kupferschmidt R, Schudt C, Wendel A, Hatzelmann A: In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors. Br J Pharmacol. 1997, 2: 221-231.","journal-title":"Br J Pharmacol"},{"key":"332_CR65","first-page":"386","volume":"3","author":"L Darwich","year":"2008","unstructured":"Darwich L, Coma G, Pe\u00f1a R, Bellido R, Blanco EJ, Este JA, Borras FE, Clotet B, Ruiz L, Rosell A, Andreo F, Parkhouse RM, Bofill M: Secretion of interferon-gamma by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18. Immunology. 2008, 3: 386-393.","journal-title":"Immunology"},{"key":"332_CR66","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ab.2010.02.036","volume":"2","author":"I Romero-Calvo","year":"2010","unstructured":"Romero-Calvo I, Oc\u00f3n B, Mart\u00ednez-Moya P, Su\u00e1rez MD, Zarzuelo A, Mart\u00ednez-Augustin O, de Medina FS: Reversible Ponceau staining as a loading control alternative to actin in Western blots. Anal Biochem. 2010, 2: 318-320.","journal-title":"Anal Biochem"},{"key":"332_CR67","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","volume":"44","author":"JP Vonsattel","year":"1985","unstructured":"Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP: Neuropathological classification of Huntington\u2019s disease. J Neuropathol Exp Neurol. 1985, 44: 559-577. 10.1097\/00005072-198511000-00003.","journal-title":"J Neuropathol Exp Neurol"}],"container-title":["Molecular Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-6606-6-55.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T23:36:32Z","timestamp":1688859392000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularbrain.biomedcentral.com\/articles\/10.1186\/1756-6606-6-55"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["332"],"URL":"https:\/\/doi.org\/10.1186\/1756-6606-6-55","relation":{},"ISSN":["1756-6606"],"issn-type":[{"value":"1756-6606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"30 July 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"55"}}